Okta (OKTA) Precio de Acción, Cotización, Noticias e Historial | Benzinga

Okta Inc (OKTA) Precio de Acción, Cotización, Noticias e Historial

OKTANASDAQ

Trade with Public

Trade with Public

$187.26

-21.26-10.2%

Últ. Act.: Oct 16, 7:46 PM

$185.70

-22.82-10.94%

Panorámica generalNoticias Previsión de beneficios Eventos Precios objetivo Finanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Estadísticas Clave

Apertura

$209.60

Cierre

$187.26

Volumen / Prom.

7.39M / 3.46M

Rango diario

$184.89 - $212.00

Rango de 52 semanas

62.66 - 235.00

Capitalización bursátil

$32.46B

Ratio PER

125.61

Rentabilidad por dividendo

-

Exchange

NASDAQ

RSI

43

Interés en corto

5.31%

Días para cubrir

1.9

Noticias Recientes de Okta, Inc.

Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today

The Nasdaq 100 fell 1.5% at midday Friday as memory chips and AI-debt names sold off, while Fed Chair Warsh declined to rule out an October hike after hot CPI and PPI. WTI held near $96, the 10-year yield hovered around 5.1%, gold bounced toward $4,200 and bitcoin traded near $81,300.

Piero Cingari

AI Breaches Cost $6 Million: 3 Security Markets Investors Should Watch

Higher breach costs give companies a reason to improve security. For investors, however, the useful question is which improvements customers will pay for and which suppliers can deliver them profitably. Answering that

Jacob Fuller

Someone Bugged OpenAI's Boardroom: ChatGPT's Maker Says its Own AI Found Out Who

OpenAI uses AI to trace a hidden office recording device to an employee who was arrested; no model weights or data were stolen.

Erica Kollmann

Nvidia, Okta, Cognex And An Industrial Stock On CNBC’s ‘Final Trades’

CNBC traders favor Nvidia, Okta, Cognex and Delta; analysts cite upside, raised targets, RealSense acquisition and upcoming earnings.

Avi Kapoor

UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’

CNBC’s final trades: Weiss picked UnitedHealth, Lebenthal chose AbbVie after FDA approval, and Terranova backed Okta amid raised price targets.

Avi Kapoor

Finanzas

Trimestral

Anual

Nombre

Ingresos Variación
Bruto Variación
EBITDA Variación
EBIT Variación
Beneficios Variación

Flujos de Caja

Flujo de Caja Operativo (TTM)

987.00M

Flujo de Caja de Inversión (TTM)

346.00M

Flujo de Caja de Financiación (TTM)

-1.45B

Flujo de Caja Libre (TTM)

959.00M

Gasto de Capital (TTM)

-28.00M

Cambio Neto en Efectivo (TTM)

-114.00M

Tendencia de los analistas

1

1

jul

34

6

ago

22

4

sept

1

1

oct

Compra

Mantener

Venta

Venta fuerte

Calificación de analistas

3.9

Compra

Compra fuerte

Compra

Mantener

Venta

Venta fuerte

Métricas de Valoración

Valor Empresarial

$30.49B

Relación P/E (TTM)

125.61

Relación P/E (FWD)

47.62

Relación PEG (TTM)

1.49

Relación P/S (TTM)

12.06

Relación P/B (TTM)

5.23

Rendimiento de Ganancias % (TTM)

0.80%

Rendimiento de Ganancias % (FWD)

2.10%

EV / EBITDA (TTM)

83.03

Precio / EBITDA (TTM)

89.95

Precio / Flujo de Caja Libre (TTM)

38.64

Valor Contable / Acción

$39.89

Deuda Empresarial

Deuda Total

-

Deuda a Largo Plazo

-

Emisión de Deuda a Largo Plazo (TTM)

-

Reembolso de Deuda a Largo Plazo (TTM)

-$860.00M

Efectivo Total

$763.00M

Deuda a Capital

0.01

Emisión de Deuda (TTM)

-$860.00M

Reembolso de Deuda (TTM)

-$860.00M